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Abstract
Background: Podoconiosis is a non-filarial elephantiasis caused by long-term barefoot exposure to volcanic soils in endemic
areas. Irritant silicate particles penetrate the skin, causing a progressive, debilitating lymphoedema of the lower leg, often
starting in the second decade of life. A simple patient-led treatment approach appropriate for resource poor settings has
been developed, comprising (1) education on aetiology and prevention of podoconiosis, (2) foot hygiene (daily washing
with soap, water and an antiseptic), (3) the regular use of emollient, (4) elevation of the limb at night, and (5) emphasis on
the consistent use of shoes and socks.
Methodology/Principal Findings: We did a 12-month, non-comparative, longitudinal evaluation of 33 patients newly
presenting to one clinic site of a non-government organization (the Mossy Foot Treatment & Prevention Association,
MFTPA) in southern Ethiopia. Outcome measures used for the monitoring of disease progress were (1) the clinical staging
system for podoconiosis, and (2) the Amharic Dermatology Life Quality Index (DLQI), both of which have been recently
validated for use in this setting. Digital photographs were also taken at each visit. Twenty-seven patients completed follow
up. Characteristics of patients completing follow-up were not significantly different to those not. Mean clinical stage and
lower leg circumference decreased significantly (mean difference -0.67 (95% CI20.38 to20.96) and22.00 (95% CI21.26 to
22.74), respectively, p,0.001 for both changes). Mean DLQI diminished from 21 (out of a maximum of 30) to 6 (p,0.001).
There was a non-significant change in proportion of patients with mossy lesions (p = 0.375).
Conclusions/Significance: This simple, resource-appropriate regimen has a considerable impact both on clinical
progression and self-reported quality of life of affected individuals. The regimen appears ideal for scaling up to other
endemic regions in Ethiopia and internationally. We recommend that further research in the area include analysis of cost-
effectiveness of the regimen.
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Introduction
Podoconiosis is a non-filarial lower-leg lymphoedema caused by
long-term barefoot exposure to volcanic soils in endemic areas[1]. It
has been described in equatorial countries across Africa, Central
and South America and South Asia and was formerly noted in
Europe before footwear became commonplace[2]. Irritant silicate
particles in areas of high altitude (over 1000 m) and annual rainfall
(over 1000 mm) penetrate the skin causing a progressive obliterative
endolymphangitis[3]. The effect is a debilitating lymphoedema of
the lower leg, with or without skin changes (hyperkeratosis and
‘mossy’ papillomata) and fibrotic nodule formation[4].
Unlike in lymphatic filariasis (LF)[5], podoconiosis lymphoede-
ma appears to affect men and women equally[6]. A cross-sectional
survey of an endemic region in Southern Ethiopia estimated a
prevalence of 5.46% in this area, which, projected to the
population now living on irritant soil in Ethiopia, suggests that
one million Ethiopians may be affected[6]. The economic burden
of the condition is considerable, with a loss of productivity
equivalent to 45% of working days per patient annually[7]. The
condition is poorly understood by the lay and medical commu-
nities alike, often being mistaken for infective filarial (Bancroftian)
elephantiasis[8]. Affected individuals find themselves socially
stigmatised, excluded from school, churches and mosques and
unable to marry into an unaffected family[9].
A simple affordable treatment approach appropriate for resource
poor settings has been developed, and shares many aspects of the
management of LF lymphoedema[10,11]. The regimen comprises
(1) training in the aetiology of podoconiosis and the rationale behind
secondary preventative measures, (2) foot hygiene, involving daily
washing with soap, water and dilute bleach (acting as an antiseptic),
(3) the regular use of emollient and/or antifungal (eg Whitfield’s
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ointment), (4) elevation of the limb at night, and (5) emphasis on the
importance of consistent use of shoes and socks[4]. In LF, foot
hygiene is effective through diminishing bacterial and fungal
infection of the swollen leg, through restoring skin integrity and
by decreasing the frequency of acute adenolymphangitis at-
tacks[10]. For podoconiosis patients, these mechanisms are also
likely to be important, and in addition, washing and the use of shoes
will lessen exposure to the environmental trigger.
Another important aspect of the treatment programme in
southern Ethiopia is educational and social support, in the form of
monthly meetings at which messages on prevention and treatment
are given, and social and spiritual support are offered. Although
evaluations of similar management regimens have been reported
in relation to filarial lymphoedema[5,12], no formal study has yet
been conducted to gather evidence on effectiveness among
podoconiosis patients. We aimed to test the effectiveness of a
community-based, patient-led treatment regimen used in southern
Ethiopia prior to scale-up of treatment efforts to other endemic
regions in Ethiopia and internationally.
Methods
Ethics Statement
This study was conducted according to the principles expressed
in the Declaration of Helsinki. The study was approved by the
School of Public Health Research Ethics Committee, Addis Ababa
University. All patients provided informed written or thumbprint
consent for their data to be analysed. The Research Ethics
Committee approved the use of thumbprint consent (counter-
signed by a witness) among illiterate patients, who constituted a
small minority of participants.
We carried out a 12-month single-centre, non-comparative study
to evaluate the treatment of newly diagnosed individuals enrolling
onto a podoconiosis management regimen in Shanto Town,
Wolaita Zone. This podoconiosis-endemic zone in southern
Ethiopia[6] is a densely populated area, where most of the
population earn a living from small-scale subsistence farming. The
management regimen evaluated forms a key part of the work of the
Mossy Foot Prevention and Treatment Association (MFPTA), a
non-governmental organisation which has been active in the area
for 10 years and currently works with over 30,000 patients[13].
New patients presenting to the clinic on a single day in June
2008 formed our cohort under study. Inclusion criteria were a
clinical assessment of non-filarial elephantiasis (clinical assessment
in this endemic area has high validity in exclusion of filarial
disease[14]), and age above 18 years. Patients were excluded from
the study if they were expecting to move out of the area during the
study period (June 2008 to June 2009) or had previously been on a
treatment programme for podoconiosis. Consent for participation
in the study was sought from patients satisfying these criteria.
Baseline data were recorded at the initial clinic visit and
treatment started immediately. Follow-up was then undertaken at
3-month intervals when the patients were established on the
treatment programme, for a total period of one year (until June
2009). Outcome measures used for the monitoring of disease
progress were (1) the clinical staging system for podoconiosis and (2)
the Amharic Dermatology Life Quality Index (DLQI). Measures
were recorded blind to previous measurements, by the same team of
fieldworkers (supervised by CS, ZZ and MA). Compliance was
evaluated using the proxy of attendance at interim clinic sessions (at
which intervention items including soap, bleach and ointment, are
distributed).
The clinical staging system for podoconiosis was modified from
the Dreyer staging system for filarial lymphoedema[11] modified
after it became clear that the disease progression of filarial and
podoconiosis lymphoedema are quite different. This staging system
has shown good content validity and good inter-observer agreement
and repeatability in the clinical assessment of podoconiosis[15]. The
Tekola clinical staging system for podoconiosis incorporates three
clinical measures – numerical stage, presence (M+) or absence (M2)
of mossy skin changes, and a measurement (in cm) of the widest
below-knee circumference. These elements are then combined and
recorded, for example ‘‘Stage 3, M+, 34’’ (see Supporting Text S1,
Tekola Staging System, for more details). Limb measurements were
made between 10am and 11am during clinic visits.
For the assessment of Quality of Life of affected individuals, the
Cardiff Dermatology Life Quality Index (DLQI)[16] translated into
Amharic, has recently been shown to have high internal consistency
and concurrent validity among podoconiosis patients[17]. The ten
questions which form the DLQI questionnaire explore diverse
aspects of quality of life, including pain, embarrassment and
interference with work and relationships. The final question raises
the issue of problems caused by the treatment itself. A higher score
indicates poorer quality of life. Digital photographs were also taken
at each visit. Patients who did not attend follow-up clinics were
visited and assessed at home by the same team of fieldworkers.
The data were analysed using the SPSS statistical package,
version 11.0. For the analysis, M+/M2 were given binary values;
all other variables retained their original numerical value. Paired
12-month differences were calculated for the four variables
(3 staging variables plus DLQI score) and checked for distribution
and skewness. The significance of the mean difference in the
numerical stage of disease, the presence or absence of mossy
changes, the circumference measurement and the DLQI score
were calculated using the sign test, McNemar’s test, a paired t test
and the sign test respectively. Ninety-five percent confidence
intervals (95% CIs) were calculated for the mean difference in
stage, leg circumference and DLQI score.
Results
33 new patients presenting at Shanto Health Centre all satisfied
the criteria for inclusion in the study and agreed to take part.
Author Summary
Podoconiosis is a type of leg swelling that occurs in the
tropics among subsistence farmers who spend long hours
in contact with irritant soil derived from volcanic parent
rock. People with this disease often live in very remote
areas far from health facilities, and do not realize that the
condition can be treated. A patient association in southern
Ethiopia has pioneered low cost treatment. We followed
27 patients with podoconiosis through their first year of
treatment. The regimen emphasizes understanding the
disease process and self-treatment through foot hygiene,
elevation of the limb at night, use of emollients, socks and
shoes. We made clinical observations, measured quality of
life and took digital photographs at the start and after 12
months of self-treatment. Leg circumference decreased by
an average of 2 cm, the stage of disease decreased
(indicating improvement) by almost one full stage. Quality
of life improved dramatically, with patients reporting levels
of life quality equivalent to non-patients. Even in a very
resource-scarce setting, we have shown that patients
benefit physically and psychologically from understanding
the disease and being shown how to look after their feet.
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Treatment started immediately and patients were followed up
between June 2008 and June 2009. During this time 6 patients
moved out of the area and were not included in our final analysis.
Baseline characteristics of these patients were not significantly
different to those who completed follow-up. Of the 27 patients
followed up, 81.5% were female. While aware that ages given are
often approximate, the age range of the sample was 18–60 years
(mean 37.4 years, median 36 years). Thirty-seven percent had at
least one affected family member. Compliance among the 27
followed up was good, only 3 patients missing one interim clinic
visit, and no patient missing more than this.
Clinical & DLQI Measurements at Baseline
Measurements taken at the first visit suggest a considerable
burden of disease in this cohort (Table 1). Over 80% of patients
presented with numerical disease stage of 2 or more, with mean
stage for the cohort of 2.07. One-third displayed mossy changes,
and leg circumference ranged from 20.0 to 35.5 cm (mean
26.22 cm,median 26.00 cm). Mean DLQI score was 21.11 (median
22.00, range 15–24) out of a possible total of 30.
Clinical & DLQI Measurements after 12 Months
After 12 months, 63.0% of patients were recorded as having
stage 1 disease with only one patient remaining at stage 3,
compared to seven at the beginning of the treatment regimen. Just
over one fifth (22.2%) still had mossy changes, while leg
circumference range had decreased to 19.0–31.0 cm (mean
24.22 cm, median 24.00 cm). The most marked change was in
mean DLQI score, which had decreased to 6.07 (median 5.00,
range 0–13) out of a possible maximum of 30. Three patients
(11.1%) reported a DLQI score of 0, suggesting a quality of life
unaffected by their condition.
Changes in Measurements Between Baseline and 12
Months
Analysis of the changes in variables from 0 to 12 months of
treatment largely confirms the statistical significance of our
findings. Clinical stage decreased in 51.9% of patients and
increased in none (mean decrease 0.67, p,0.001, 95% CI 0.38
to 0.96). Changes in clinical stage from baseline to one year are
shown graphically in Figure 1. Mean reduction in leg circumfer-
ence was 2.00 cm (p,0.001, 95% CI 1.26 to 2.74), with 85.2% of
patients showing a decrease of at least 1 cm. Every patient
reported a reduced DLQI score and for 96.3% of patients this was
a change of 10 points or more. Mean decrease in DLQI score was
15.04 (p,0.001, 95% CI 213.32 to 216.76). The only variable
not showing a statistically significant treatment effect after 12
months was the presence of mossy changes. Four patients had lost
and one patient gained mossy lesions, with a p-value for these
changes of 0.375.
Discussion
This simple, resource-appropriate, lymphoedema management
regimen is effective in improving clinical outcomes and self-
reported quality of life of people affected with podoconiosis.
Before discussing the improvements observed in comparison
with other studies, the limitations of this follow-up study must be
acknowledged. The most important of these is the lack of an
untreated control group. In common with other groups faced with
evaluating lymphoedema management regimens already adopted
by communities (LeAnne Fox, personal communication), we found
it ethically difficult to deny affected individuals access to the
regimen because of strong observational evidence in favour of the
treatment. Podoconiosis lymphoedema has never been reported as
regressing of its own accord, making it likely that the improve-
ments observed are attributable to the management regimen. This
small, observational pilot study suggests the need to conduct a
formal randomized controlled trial of lymphoedema management
among podoconiosis patients. This might be achieved ethically by
randomizing patients or communities to ‘immediate’ or ‘delayed’
treatment, with outcomes compared between groups after one
year, prior to starting treatment in the ‘delayed’ group. Several
organizations, government and non-government, are planning
introduction of podoconiosis control measures in endemic areas of
Ethiopia in which no treatment is currently available, and the
initial stages might provide ideal settings for a trial of this type.
It is possible that the participants followed were to some extent
self-selecting, and may therefore represent those with a higher
level of commitment to treatment than the entire podoconiosis
population from which they came. As this was a piece of
operational research, however, it was important not to alter the
process of selection already in place. It is difficult to know whether
the gender imbalance of the sample affected our findings.
Subgroup analysis by sex showed slightly greater changes in all
variables for men than for women, but none of these comparisons
was statistically significant.
Loss to follow-up was experienced in 6/33 (18%) of the cohort.
Comparison of demographic and clinical characteristics between
those completing follow up and those lost to follow up did not
suggest significant differences in these factors among those lost to
Table 1. Changes in clinical variables and DLQI from baseline to 12 months.
0 months 12 months Mean difference (95% CI) p-value
Clinical Stage Mean 2.07 1.41 20.67 ,0.001
Clinical Stage Range 1 to 3 1 to 3 20.38 to 20.96
Circumference mean (cm) 26.22 24.22 22.00 ,0.001
Circumference range (cm) 20 to 35 19 to 31 21.26 to 22.74
DLQI Mean 21.11 6.07 215.04 ,0.001
DLQI Range 15 to 24 0 to 13 213.32 to 216.76
Number (%) losing/gaining moss
Moss present (%) 9 (33.3) 6 (22.2) 4 (14.8)/1 (3.7) 0.375
DLQI = Dermatology Life Quality Index.
CI – Confidence Interval.
doi:10.1371/journal.pntd.0000902.t001
Effectiveness of a Podoconiosis Treatment Regimen
www.plosntds.org 3 November 2010 | Volume 4 | Issue 11 | e902
follow up, thus bias related to follow-up is unlikely to have been
introduced.
In order to minimise observer bias, fieldworkers who recorded
both clinical stage and DLQI were blind to the patients’ previous
scores. Level of compliance (regularity of emollient application,
washing, elevation and shoe use) was not monitored, limiting the
extent to which we can measure a ‘dose-effect’ of the treatment. In
particular, availability of water to wash with was not ensured by
the program, and during the final 4 months of self-treatment
(towards the end of the dry season), some patients reported this to
be a limiting factor. This evaluation is therefore highly pragmatic,
representing podoconiosis treatment as implemented in the ‘real
world’ in rural Ethiopia.
After twelve months of treatment, we observed small but
significant changes in clinical outcomes. Clinical stage decreased in
more than half of patients, with a mean decrease of 0.67 stage.
The Tekola clinical staging system has been shown to have high
inter-observer agreement and to be highly repeatable over 1
week[15], but it is possible that the fieldworkers were influenced by
a form of ‘social desirability’ bias when presented with borderline
cases, resulting in recording of lower disease stage at 12 months.
Lower leg circumference is a less subjective measure, and
decreased on average by 2 cm or 7.5% of the original. We did
not measure leg volume, but extrapolation from a 2 cm decrease
in circumference suggests a clinically as well as statistically
significant change. We were unable to take biopsies in this very
remote rural setting, and have no information on reversal of
pathological changes associated with these clinical changes.
Addiss’s group in Haiti studied the effectiveness of 12 months
lymphoedema management on histological markers of chronic
inflammation in LF patients. They demonstrated distinct
improvements (reduction in perivascular and periadnexal infil-
trates, reduction in deep dermal fibrosis) in the 27 patients
studied[5].
Initial average quality of life score, at 21 units, was higher than
the average recorded (13 units) among previously untreated
patients at another treatment site in 2007[17], or among filarial
lymphoedema patients using the modified DLQI (8 units[18]). At
15 units the average decrease in DLQI over 12 months was larger
than the difference between treated and new podoconiosis patients
(10 units[17]). It is unclear to what extent this is due to tangible
clinical change, rather than simply a consequence of the social and
community aspects of the intervention. A similar study, reporting
the effect of lymphoedema management on quality of life among
15 lymphatic filariasis patients in Guyana also showed significant
decrease in DLQI. Mean DLQI fell from 10.9 to 4.1 (p,0.0001),
and the author suggested several possible reasons for this
improvement, including increased ability to work and perform
daily functions, empowerment in relation to the condition and its
management, and ability to network with other patients[12].
No previous follow up studies of lymphoedema management in
podoconiosis have been reported. We recommend that further
research in the area could include analysis of the cost-effectiveness
of the programme, establishing a treatment cost per unit
improvement in each variable. Also currently lacking is a
qualitative exploration of patients’ perceptions of the treatment
and its key elements. As the programme is introduced to new areas
it will also be important to assess its impact with ‘before and after’
trials. The implications of our findings have the potential to be far-
reaching. This simple patient-led approach is feasible even in very
remote rural areas, and appears ideal for scaling up to other
podoconiosis-endemic regions in Ethiopia and internationally.
The regimen has considerable overlap with that suggested for
control of LF morbidity[10], so we recommend that expansion of
podoconiosis control is integrated with that of LF control in
countries where both forms of lymphoedema contribute signifi-
cantly to morbidity.
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